Dateline City: DURHAM, N.C. Company will host lunch symposium to highlight implications of findings on treatment of coronary bifurcation lesions on Tuesday, October 13th at 11:30am PDT. DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced the company will present results from the Tryton Confirmatory Study, a pivotal single-arm clinical trial …
Tryton Medical Announces Publication of Post Hoc Analysis of Randomized Clinical Trial in Treatment of Bifurcation Lesions using Tryton Side Branch Stent
Dateline City: DURHAM, N.C. Analysis showed reductions in target vessel failure and improved side branch percent diameter stenosis in patients with a coronary bifurcation lesion in vessels 2.25mm in diameter or greater DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat coronary bifurcation lesions, today announced that results of a post hoc analysis of the pivotal …
Tryton Medical Announces Completion of Enrollment in the EXTENDED ACCESS Registry for its Tryton Side Branch Stent
Dateline City: DURHAM, N.C. Tryton remains on schedule to file pre-market approval application for its Side Branch Stent in 2015 DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced the completion of enrollment in the Extended Access Registry, a single arm study of its Tryton Side Branch Stent. The Tryton registry is …
Tryton Medical Announces Publication of Data from Pivotal Trial for Tryton Side Branch Stent in Journal of American College of Cardiology
Dateline City: DURHAM, N.C. Results from largest study in treatment of coronary bifurcations demonstrate reductions in TVF and side branch percent stenosis in intended population of patients with complex lesions involving significant side branches DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents to treat bifurcation lesions, today announced that results from the company’s pivotal clinical trial for the …
Global Bifurcation Leader Tryton Medical Announces Events at TCT 2014
Press release TCT 2014 announcement – Sep 12
Tryton Medical Enrolls First U.S. Patient in the EXTENDED ACCESS Registry
Tryton Medical Enrolls First U.S. Patient in the EXTENDED ACCESS Registry
Tryton Medical Completes $20 Million Equity Financing
Tryton Medical Financing September 2014 Press Release
Tryton Medical Enrolls First Patient in the EXTENDED Access Registry
Dateline City: DURHAM, N.C. A Single Arm Study Designed to Support FDA Submission for US Approval DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents to treat bifurcation lesions, announced that the first patient has been enrolled in the EXTENDED Access Registry (Tryton IDE XA registry), a single arm study of its Tryton Side Branch Stent. The Tryton IDE …
EuroPCR 2014 Events Announcement
EuroPCR 2014 Events Announcement
Tryton Medical Announces Events at EuroPCR 2014 in Paris
Dateline City: DURHAM, N.C. DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced activities highlighting the latest data and experience with the Tryton Side Branch Stent at EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions, taking place at the Palais des Congrès May 20-23, 2014 in Paris. The …